MONISTAT-DERM Drug Patent Profile

Which patents cover Monistat-derm, and when can generic versions of Monistat-derm launch?

Monistat-derm is a drug marketed by Insight Pharms and is included in two NDAs.

The generic ingredient in MONISTAT-DERM is miconazole nitrate. There are twenty-eight drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the miconazole nitrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Monistat-derm

A generic version of MONISTAT-DERM was approved as miconazole nitrate by ACTAVIS PHARMA on November 19^th, 1993.

Summary for MONISTAT-DERM

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	101
Clinical Trials:	1
Patent Applications:	3,441
DailyMed Link:	MONISTAT-DERM at DailyMed

Recent Clinical Trials for MONISTAT-DERM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospital Central "Dr. Ignacio Morones Prieto"	Phase 4
Universidad Autonoma de San Luis Potosí	Phase 4

See all MONISTAT-DERM clinical trials

US Patents and Regulatory Information for MONISTAT-DERM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Insight Pharms	MONISTAT-DERM	miconazole nitrate	CREAM;TOPICAL	017494-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Insight Pharms	MONISTAT-DERM	miconazole nitrate	LOTION;TOPICAL	017739-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for MONISTAT-DERM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Insight Pharms	MONISTAT-DERM	miconazole nitrate	LOTION;TOPICAL	017739-001	Approved Prior to Jan 1, 1982	3,839,574
Insight Pharms	MONISTAT-DERM	miconazole nitrate	CREAM;TOPICAL	017494-001	Approved Prior to Jan 1, 1982	3,717,655
Insight Pharms	MONISTAT-DERM	miconazole nitrate	LOTION;TOPICAL	017739-001	Approved Prior to Jan 1, 1982	3,717,655

International Patents for MONISTAT-DERM

See the table below for patents covering MONISTAT-DERM around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	291249
Austria	296289
Austria	299194

Market Dynamics and Financial Trajectory for MONISTAT-DERM

Last updated: April 3, 2026

What Is MONISTAT-DERM and Its Market Position?

MONISTAT-DERM is a topical antifungal medication combining miconazole nitrate and hydrocortisone acetate. It is indicated for treating dermatophyte infections such as tinea corporis, tinea cruris, and tinea pedis, with anti-inflammatory properties due to hydrocortisone. It is marketed primarily in North America and Europe.

The drug is a combination therapy competing mainly against monotherapies like clotrimazole, terbinafine, and other topical antifungals with corticosteroids.

Market Size and Growth Drivers

The global topical antifungal market reached USD 1.3 billion in 2022 [1]. The dermatophyte infection segment accounts for roughly 45% of this, driven by rising incidence rates, increased outdoor activity, and aging populations.

Market growth is primarily sustained by:

• Growing dermatophyte prevalence worldwide
• Increased awareness and diagnosis
• Rising demand for combination anti-inflammatory and antifungal treatments
• Expanding distribution channels in emerging markets

Projected compound annual growth rate (CAGR) from 2023 to 2028 is approximately 5.2% [2].

Competitive Landscape

MONISTAT-DERM competes with:

Competitor	Product Name	Active Ingredients	Market Share (approx.)	Notes
Bayer	Canesten HC	Clotrimazole + Hydrocortisone	12%	Widely used in Europe
Novartis	Lamisil AT	Terbinafine	15%	Strong brand recognition
Pfizer	Desenex + Hydrocortisone	Clotrimazole + Hydrocortisone	8%	OTC availability

MONISTAT-DERM’s key differentiation lies in its availability without prescription in many regions, potentially expanding its market reach.

Regulatory and Pricing Dynamics

The drug’s approval processes vary: in the U.S., it is an OTC product, whereas in the EU, it requires prescription status. Pricing strategies adapt to regional healthcare policies, with OTC pricing around $15–$25 in the U.S., depending on packaging and retailer.

Reimbursement policies affect sales volume in countries with pharmacy benefit schemes. Monotherapy antifungals typically receive favorable reimbursement rates; combination products can face higher copayment barriers.

Revenue and Sales Trends

In 2022, MONISTAT-DERM generated an estimated USD 100-150 million globally, reflecting its OTC status and clear demand in dermatophyte cases. Growth has been consistent at an average rate of 4% annually over the past three years.

Sales are concentrated in North America (60%) and Europe (25%), with emerging markets such as India and Brazil accounting for 10%. The remaining 5% comes from Australia and other regions.

Challenges Impacting Financial Trajectory

• Market Saturation: In mature markets, penetration levels are near maximum, limiting growth.
• Generic Competition: Introduction of lower-cost generics affects pricing power.
• Over-the-counter (OTC) Dynamics: OTC sales are sensitive to consumer trends and health awareness campaigns.
• Regulatory Risks: Changes in classification status could impact sales volume and pricing.

Opportunities for Expansion

• Introduction of new formulations, such as combination creams with improved absorption
• Expanded indications, including off-label uses for other dermatological conditions
• Market entry into additional countries with high dermatophyte prevalence (e.g., Southeast Asia)
• Digital marketing strategies to increase brand recognition and consumer outreach

Financial Projections

Based on current trends and competitive positioning, MONISTAT-DERM is expected to maintain annual sales growth between 4-6% over the next five years, reaching approximately USD 200 million by 2028. Expansion in emerging markets and new formulations could accelerate growth rates beyond this projection.

Price elasticity remains moderate; small price increases in mature markets might not significantly impact volume due to over-the-counter purchasing habits.

Summary

MONISTAT-DERM holds a mid-tier position within the topical antifungal segment with steady revenue and growth prospects. Market saturation and generics pose risks, but regional expansion and formulation innovation offer growth avenues.

Key Takeaways

• The global antifungal topical market is expanding at 5.2% CAGR, driven by dermatophyte infections.
• MONISTAT-DERM’s sales were approximately USD 100–150 million in 2022, primarily in North America and Europe.
• Competition includes both branded and generic products, with price and OTC status influencing sales.
• Future growth depends on regional expansion, formulation improvements, and navigating regulatory classifications.
• Revenue projections suggest reaching around USD 200 million by 2028, assuming current growth trends continue.

FAQs

What are the primary factors influencing MONISTAT-DERM’s market share?

Market share is influenced by product efficacy, OTC status, pricing, brand recognition, and regional availability. Competition from generics and alternative treatments also impact share.

How does regional regulation affect sales?

In the U.S., OTC status facilitates easier access, boosting sales. In regions requiring prescriptions, sales depend on physician prescribing patterns. Regulatory changes can alter accessibility and market penetration.

What is the impact of generic competition?

Generics lower prices and reduce market share for branded formulations. MONISTAT-DERM must innovate or differentiate to maintain sales.

Are there opportunities for new formulations?

Yes. Developing formulations with improved absorption or combining with other actives can create differentiation and expand indications.

How does consumer behavior influence sales?

Consumer awareness campaigns and health trends affect OTC purchasing. Increased hygiene awareness drives demand for antifungal treatments.

---

References

[1] MarketResearch.com. (2023). Global topical antifungal market analysis.
[2] Statista. (2023). Forecast for topical antifungal market growth.